Suppr超能文献

主动脉瘤和血管畸形相关弥散性血管内凝血的处理。

Management of disseminated intravascular coagulation associated with aortic aneurysm and vascular malformations.

机构信息

Department of Hematology, Kanazawa University Hospital, 13-1 Takaramachi, Kanazawa, Ishikawa, 920-8641, Japan.

出版信息

Int J Hematol. 2021 Jan;113(1):15-23. doi: 10.1007/s12185-020-03028-z. Epub 2020 Nov 11.

Abstract

Aortic aneurysms and vascular malformations are sometimes associated with disseminated intravascular coagulation (DIC). A typical blood coagulation test shows decrease in platelet count and fibrinogen, and increases in fibrin/fibrinogen degradation products (FDP) and D-dimer. The coagulation activation marker thrombin-antithrombin complex (TAT) and the fibrinolysis activation marker plasmin-α plasmin inhibitor (PIC) are significantly increased. α plasmin inhibitor (αPI) is significantly reduced. Since no prolongation of prothrombin time (PT) is noticeable and activated partial thromboplastin time (APTT) is shortened in some cases, DIC cannot be diagnosed or ruled out by PT and APTT alone. The cornerstone of treatment for DIC is to treat the underlying disease. However, surgery is not possible in some cases. Follow-up may be appropriate in patients with abnormal results from coagulation tests and no bleeding. However, pharmacotherapy is often required in cases with bleeding. Unfractionated heparin, low molecular weight heparin, protease inhibitors, recombinant thrombomodulin, direct oral anticoagulants, and factor XIII preparations are effective. If PIC is significantly increased and αPI is significantly decreased, or if the bleeding is severe, tranexamic acid is used as an antifibrinolytic therapy with anticoagulant therapy. In such cases, attention should be paid not only to TAT but also changes in PIC.

摘要

主动脉瘤和血管畸形有时与弥散性血管内凝血 (DIC) 有关。典型的凝血检测显示血小板计数和纤维蛋白原减少,纤维蛋白/纤维蛋白原降解产物 (FDP) 和 D-二聚体增加。凝血激活标志物凝血酶-抗凝血酶复合物 (TAT) 和纤维蛋白溶解激活标志物纤溶酶-α 纤溶酶抑制剂 (PIC) 显著增加。α 纤溶酶抑制剂 (αPI) 显著减少。由于凝血酶原时间 (PT) 没有明显延长,且部分情况下激活部分凝血活酶时间 (APTT) 缩短,因此不能仅通过 PT 和 APTT 诊断或排除 DIC。DIC 的治疗基石是治疗基础疾病。然而,在某些情况下手术是不可能的。对于凝血检测结果异常且无出血的患者,可进行随访。然而,在有出血的情况下,通常需要药物治疗。未分级肝素、低分子量肝素、蛋白酶抑制剂、重组血栓调节蛋白、直接口服抗凝剂和因子 XIII 制剂有效。如果 PIC 显著增加且 αPI 显著减少,或者出血严重,可使用氨甲环酸进行抗纤维蛋白溶解治疗联合抗凝治疗。在这种情况下,不仅要注意 TAT,还要注意 PIC 的变化。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验